Publications
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
.
2016. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials.. Clin Interv Aging. 9:2065-77.
.
2014. Epistasis analysis links immune cascades and cerebral amyloidosis.. J Neuroinflammation. 12:227.
.
2015. Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
.
2016. E.U./U.S. CTAD Task Force on Alzheimer's Trial Populations. J Prev Alz Dis. 1:110-116.
.
2014. Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates.. Alzheimers Dement (Amst). 9:21-24.
.
2017. Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife.. Neuroimage Clin. 14:760-774.
.
2017. Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.. J Intern Med. 275(3):304-16.
.
2014. Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation.. Neuroimage. 129:1-14.
.
2016. How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease? Neurodegener Dis. 13(2-3):197-9.
.
2014. Identifying incipient dementia individuals using machine learning and amyloid imaging.. Neurobiol Aging. 59:80-90.
.
2017. Imaging biomarkers for amyloid: a new generation of probes and what lies ahead.. Int Psychogeriatr. 26(5):703-7.
.
2014. Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone.. J Cereb Blood Flow Metab. 35(7):1169-74.
.
2015. In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.. Brain Struct Funct.
.
2015. In vivo quantification of neurofibrillary tangles with [F]MK-6240.. Alzheimers Res Ther. 10(1):74.
.
2018. In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals.. Transl Neurodegener. 3(1):6.
.
2014. Measuring the impact of cognitive and psychosocial interventions in persons with mild cognitive impairment with a randomized single-blind controlled trial: rationale and design of the MEMO+ study.. Int Psychogeriatr. 27(3):511-25.
.
2015. MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.. Trends Neurosci. 37(11):629-41.
.
2014. The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.. J Alzheimers Dis. 56(3):929-938.
.
2017. Mild cognitive impairment: a concept in evolution.. J Intern Med. 275(3):214-28.
.
2014. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain.. Alzheimers Res Ther. 9(1):25.
.
2017. Multicenter Validation of an MMSE-MoCA Conversion Table.. J Am Geriatr Soc. 65(5):1067-1072.
.
2017. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
.
2017. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 88(19):1814-1821.
.
2017. .
2019.